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Purpose: To investigate the association of meibomian gland 
dysfunction severity and glycated hemoglobin A (HbA1c) levels 
among type 2 diabetic patients.
Patients and Methods: In this cross-sectional study, 40 type 2 diabetic 
patients with meibomian gland dysfunction (MGD) were studied at 
Basir Eye Clinic, Tehran, Iran. An expert ophthalmologist determined 
the MGD stage based on staging scale outlined in American academy 
of ophthalmology’s basic and clinical science course. The HbA1c 
level was measured applying a standard method, certified by the 
National Glycohemoglobin Standardization Program (NGSP). We 
divided patients to two groups based on their HbA1c level; the first 
group included patients with HbA1c < 6.5 % and the second group 
included patients with HbA1c ≥ 6.5  %.
Results: Our results demonstrated that 12.5 % of the participants had 
minimal, 52.5 % had mild and 35 % had moderate to severe MGD. We 
observed that different levels of HbA1c (over or under 6.5 %) were 
significantly associated with MGD severity (P < 0. 013). Moderate to 
severe MGD stage was observed in 43.7 % of individuals with HbA1c 
≥ 6.5 %, while it was found in none of participants with HbA1c < 6.5 %. 
With increase in HbA1c level, the risk of moderate to severe MGD 
occurrence increased (OR =  3.57; 95  % CI: 1.05-12.13; P  = 0.041). 
This association was not confounded by age or gender.  
Conclusion: Meibomian gland dysfunction severity has an association 
with HbA1c levels in diabetic type 2 patients, and a rise in HbA1c 
noticeably aggravates the MGD stage.
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Introduction
Type 2 diabetes mellitus, with increasing 
number of affected people due to aging, 
urbanization, physical inactivity and obesity, 
is a main cause of worldwide socioeconomic 
burden and mortality. It is more prevalent 
among 45 to 64 year old and over 64 year 
old population in developing and developed 
countries, respectively 1. According to the first 
survey of risk factors for non-communicable 
diseases in Iran (2005) the overall incidence of 
diabetes had reached 7.7 % among adults aged 
25-64 year old 2. 
HbA1c or glycated hemoglobin indicates the 
mean blood sugar level over the lifetime of 
red blood cells. HbA1c is considered as the 
gold standard test for diabetes assessment and 
management 3. 
Despite the abundance of literature concerning 
complications of diabetes, there are few 
studies regarding the relation between diabetes 
and dry eye. Recent studies have indicated 
the toxic nature of hyperglycemia and insulin 
resistance on human meibomian gland 
epithelial cells 4. Meibomian glands supply 
the tear film lipid component and play a major 
role in ocular surface health 4-6. Diabetes 
impairs sebaceous glands function 7-9 and 
has a key role in development of meibomian 
gland dysfunction (MGD). MGD blocks 
meibomian glands openings, increases tear 
film osmolarity and evaporation and causes 
an inflammation leading to eye irritation 10- 11. 
MGD is considered as the most common cause 
of dry eye and patient visit due to eye irritation 
and foreign body sensation 12.
The higher prevalence of dry eye and MGD 
in diabetes is well-defined in the literature. 
However, to the best of our knowledge there 
is no study evaluating the relation between 
HbA1c in patients with type 2 diabetes and 
the severity of MGD, so the present cross-
sectional study was conducted to study the 
correlation between HbA1c levels and the 
MGD severity among these patients. 
Patients and Methods
The present study was a cross-sectional study 
including 40 type 2 diabetic patients with 
MGD. Patients with a history of any refractive 
surgery, thyroid eye disease, pterygium, and 
antihistamines and tricyclic antidepressants 
usage in last one year were excluded. The 
study was approved by the ethics committee 
of Basir Eye Health Research Center, Tehran, 
Iran, and written consent was provided by all 
participants before entering the study.
The diabetic state was evaluated according 
to the American Diabetes Association 
guidelines 13. The HbA1c level was measured 
using a standard method, certified by the 
National Glycohemoglobin Standardization 
Program (NGSP) 14.
A single expert ophthalmologist examined all 
patients and determined the MGD based on 
staging scale outlined in American Academy 
of Ophthalmology’s Basic and Clinical 
Science Course (Table 1) 10,15. Finally, Patients 
were divided based on their HbA1c level into 
2 main groups including HbA1c < 6.5 %, and 
≥ 6.5 %; then the correlation of HbA1c and 
MGD stage was evaluated. 
Statistical analysis
Chi-square and multinomial logistic regression 
tests were used when appropriate to evaluate 
the data. SPSS version 21 (Armonk, NY: 
IBM Corp.) was used for statistical analysis. 
P values less than 0.05 were considered 
significant. 
Results
The mean age of participants in the present 
study was 58.45 ± 6.32. The male to female 
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ratio was 14/26. The mean age of diabetic 
females and males were 58.96 ± 4.43 and 
57.50 ± 8.97 years, respectively. 
The mean HbA1c was 7.92 ± 2.15 with a 
mean blood glucose level of 190.45 ± 53.10. 
We observed that HbA1c levels significantly 
differed in each MGD stage (P < 0.013) 
(Table 2). Moderate to severe MGD stage 
was observed in 43.7 % of individuals with 
HbA1c ≥ 6.5 %, while it was found in none 
of participants with HbA1c between < 6.5 % 
(Table 2). With increase in HbA1c level, the 
risk of moderate to severe MGD occurrence 
increased remarkably (OR = 3.57; 95 % CI: 
1.05-12.13; P = 0.041). This association was 
not confounded by age or gender.  
Discussion
In the present study MGD severity was found 
to be associated with HbA1c levels among 
type 2 diabetic patients. Subsequently, higher 
HbA1c levels predicted more severe MGD, 
independent of age and sex of the participants. 
Some previous studies have compared 
the prevalence of dry eye in patients 
suffering from diabetes mellitus and normal 
population. Diabetes is a known risk factor 
for impairment of sebaceous glands function 
since hyperglycemia and insulin resistance 
pose a dose-dependent toxic effect on human 
meibomian gland epithelial cells 9,16. The 
prevalence of dry eye has shown a correlation 
with higher values of glycated hemoglobin 17. 
Table 1: Clinical summary of the MGD staging 10
Stage MGD * grade Symptoms Corneal staining
1 + (Minimally altered expressibility and 
secretion quality)
None None
2 ++ (Mildly altered expressibility and 
secretion quality)
Minimal to mild None to limited
3 +++ ( Moderately altered expressibility 
and secretion quality)
Moderate Mild to moderate; 
mainly peripheral
4 ++++ (Severely altered expressibility and 
secretion quality)
Marked Marked: central in 
addition
Table 2: Association between HbA1c level and MGD stages
HbA1C MGD




< 6.5 % Count 3 5 0 8
0.013≥ 6.5 % Count 2 16 14 32
Total Count 5 21 14 40
*Chi-Square test
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Moreover, diabetes aggravates peripheral 
neuropathy, which leads to impairment of 
corneal sensation and the consequent decline 
in tear production 18. Shamsheer et al., 6 
compared the prevalence and severity of MGD 
between diabetic patients and non-diabetic 
individuals. They reported that corneal staining 
and meibomian gland secretion volumes are 
significantly deteriorated in diabetic patients. 
However, they did not evaluate HbA1c or 
blood sugar levels 6. 
Studies on MGD frequency have shown a wide 
range due to lack of consensus on standardized 
clinical criteria for MGD. However, in most 
studies MGD is measured based on frequency 
of eye dryness, gritty/sandy sensation, burning 
sensation, sticky sensation, watering/tearing, 
redness, crusting/discharge, and eyes stuck 
shut 6. The prevalence of MGD differs in the 
literature from 3.5 % to 70 % of population with 
the greatest incidence in Asian population 19. 
Hom et al., 19 reported 38.9 % prevalence of 
MGD in a group of 398 randomly selected, 
apparently normal, participants presenting for 
routine vision examinations 19. We found that 
87.5 % of our patients with type 2 diabetes 
had self-reported, clinically relevant mild to 
severe MGD. 
Although our results revealed that the severity 
of MGD is significantly increased when higher 
HbA1c levels are present, the mechanism of 
this phenomenon is yet to be fully understood. 
It is known that peripheral neuropathy 
gradually damages Aδ and unmyelinated 
C-class small nerve fibres 20. Deterioration 
of corneal nerves might result in reduction of 
subbasal nerve density and branching, which 
together will reduce the corneal sensitivity 21. 
This reduced corneal sensitivity lowers the 
blink rate, which might subsequently cause 
increased tear evaporation 22. Decreased 
corneal sensitivity might also influence the 
control of orbicularis and Riolan’s muscles, 
which are responsible for the delivery of the 
lipid to the lid margin 23; and this change might 
be a reason for increased frequency of MGD 
in type 2 diabetic patients. The other proposed 
mechanism is that MGD might be induced 
by the concomitant inflammatory response in 
patients with diabetes. It is well-documented 
that in diabetic patients free fatty acids (FFAs) 
in plasma create insulin resistance 24 and 
enhance the expression and release of pro-
inflammatory cytokines 25. Further studies are 
needed to link increased FFA in meibomian 
glands with accumulation of meibum leading 
to meibomitis in diabetic patients.
To the best of our knowledge, the present study 
was the first study evaluating the correlation 
between HbA1c levels in type 2 diabetic 
patients and MGD severity. The HbA1c is 
the most worldwide accepted marker for 
measuring glycemic control and providing 
long-term metabolic monitoring in patients 
with diabetes 26. 
The present study had some limitations 
including the small sample size and not 
taking into account the blood sugar levels or 
the clinical severity of diabetes. Moreover, 
we collected our data during a cold-weather 
period, which might have aggravated dry eye 
conditions among our patients 27. 
Conclusion
Meibomian gland dysfunction severity has 
an association with HbA1c levels in diabetic 
type 2 patients, and a rise in HbA1c noticeably 
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